Siramesine H Lundbeck
by
Heading C.
moore11@globalnet.co.uk
Curr Opin Investig Drugs. 2001 Feb;2(2):266-70

ABSTRACT

Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].

Antidepressants
Enkephalinase inhibitors
Sigma agonists and pain
Igmesine: sigma ligand and antidepressant
Sigma-receptor ligands and anti-stress actions

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family